InvestorsHub Logo
Followers 1
Posts 52
Boards Moderated 0
Alias Born 10/20/2014

Re: trading.jeff post# 29272

Saturday, 03/21/2015 10:31:21 PM

Saturday, March 21, 2015 10:31:21 PM

Post# of 48316
trading.jeff,

I think it is the opposite. The fact that Merck obviously hands out Keytruda to anyone willing to try a combination trial negates the notion that ONCS is somehow special just because Pierce used to work for Merck. ONCS may have a good hypothesis for combining Immunopulse with Keytruda (I like that hypothesis as well or else I would not be invested/interested in this stock), but make no mistake, that did not make ONCS special to Merck. ONCS still has to prove it works, just like all of the other researchers that Merck has supplied Keytruda to.



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCSQ News